In the Spotlight...

B cell-derived IL-27 promotes control of persistent LCMV infection

Using IL-27p28 reporter mice, Pratumchai et al. showed that IL-27-producing B/plasma cells are essential for control of persistent LCMV infection. Mice lacking IL-27 receptor (IL-27ra) expression in B...

REVIEW: Tertiary lymphoid structures in cancer

Schumacher and Thommen provided an overview of tertiary lymphoid structures (TLSs) and highlighted their growing recognition as a marker of and/or contributor to clinical outcomes and responses to imm...

Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

Compared to recombinant WT human (rh) IL-2, Merchant et al. showed that MDNA11, a mutated rhIL-2 fused to human albumin, had higher binding affinity for human, cynomolgus monkey, and mouse IL-2Rβ (CD1...

HLA-independent T cell receptors for targeting tumors with low antigen density

Mansilla-Soto et al. generated TRAC-HIT T (HIT) cells with TRAC KO and specificity for CD19 conferred to the TCR–CD3 complex by changing the peptide:MHC-binding portion of the TCR to match the VH/VL d...

Previous Digests

New year, new IL-12

January 19, 2022

Strategies to activate tumor-infiltrating lymphocytes (TILs) can support existing cancer therapies and overcome resistance mechanisms such as exhaustion. One such approach, the inflammatory cytokine IL-12, can activate T cells and may be linked to patient survival, but its application...

With the powers of the immunoproteasome, MSCs can become APCs

January 12, 2022

Over the years, dendritic cell (DC) vaccines have consistently shown promise, but have come up short in the clinic, potentially due to poorly presented antigens, limited in vivo persistence, or impaired function when derived autologously from patients with cancer. As...

First-in-class vaccine against IDO and PD-L1 enhances anti-PD-1 in phase I/II clinical trial

December 22, 2021

Drugs targeting the PD-1/PD-L1 axis, like nivolumab, have revolutionized treatment of patients with metastatic melanoma. However, many patients still either do not respond or develop resistance to therapy. In an effort to modulate tumor microenvironments (TMEs) to enhance responses...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

Taylor Lord

Taylor Lord

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.